EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study

Zhenzhen Zhang, Meixia Wang, Guobin Chen, Yanfang Wu, Xiaochun Chen, Xinkun Guo, Boheng Zhang

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04255-1 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Zhenzhen Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Oncology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen Clinical Research Center for Cancer Therapy, Clini…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Quinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Foundation of Science and Technology Bureau of Xiamen, Bethune Charitable Foundation, the Natural Science Foundation Project of Xiamen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hepatic arterial infusion chemotherapy (HAIC) provides sustained high intrahepatic drug exposure with limited systemic toxicity, potentially enhancing antigen release and immune sensitization. This study compared the efficacy and safety of HAIC combined with lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy-based triple therapy in advanced unresectable intrahepatic cholangiocarcinoma (iCCA). METHODS: A retrospective analysis of 67 patients with unresectable iCCA treated with HAIC-based triple therapy (n = 32) or systemic triple therapy (n = 35) was conducted. Clinical efficacy, survival, prognostic factors and safety profiles were evaluated. Baseline imbalances were adjusted using inverse probability of treatment weighting (IPTW). Kaplan-Meier and Cox regression analyses before and after IPTW assessed treatment effects on overall survival (OS) and progression-free survival (PFS). RESULTS: HAIC-based triple therapy achieved superior tumor control versus systemic therapy, with higher objective response rate (59.4 vs. 20.0%; P < 0.001), disease control rate (90.6 vs. 68.6%; P < 0.001), and tumor shrinkage (+ 6.5 vs. - 1.0 mm; P = 0.002). Local (93.8 vs. 66.7%; P = 0.006) and distant (90.3 vs. 72.7%; P = 0.071) control rates favored HAIC-based triple therapy. After IPTW adjustment, Kaplan-Meier survival analysis showed that HAIC-based triple therapy significantly improved both OS (24.1 vs. 15.5 months; P = 0.010) and PFS (P = 0.020) compared to systemic therapy. In the IPTW-adjusted multivariate Cox regression analysis, HAIC-based triple therapy was associated with a markedly reduced risk of OS (HR [95% CI]: 0.221[0.070-0.693]) and PFS (HR[95% CI]: 0.129[0.028-0.592]). Toxicities were manageable, and immune-related adverse events correlated with reduced progression. CONCLUSION: HAIC-based triple therapy provided superior tumor control, prolonged survival, and preserved hepatic function with acceptable safety in unresectable iCCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsQuinolinesBile Duct NeoplasmsPhenylurea CompoundsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedInfusions, Intra-ArterialProgrammed Cell Death 1 ReceptorB7-H1 AntigenAdultHepatic Artery

Stichwörter der Autor:innen

BiomarkersHAICIntrahepatic cholangiocarcinomaLenvatinibPD-1/PD-L1 inhibitorSurvival

Substanzen

lenvatinibImmune Checkpoint InhibitorsQuinolinesPhenylurea CompoundsProgrammed Cell Death 1 ReceptorCD274 protein, humanB7-H1 AntigenPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Oncology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen Clinical Research Center for Cancer Therapy, Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujia…
  • Department of Hospital Infection Management, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, Fujian, 361015, People's Republic of China.

Förderung

  • the Foundation of Science and Technology Bureau of Xiamen
  • Bethune Charitable Foundation
  • the Natural Science Foundation Project of Xiamen
  • the Foundation of the Natural Science Foundation of Fujian Province

Zitieren

APA

Zhang, Z., Wang, M., Chen, G., Wu, Y., Chen, X., Guo, X., & Zhang, B. (2025). Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04255-1

Vancouver

Zhang Z, Wang M, Chen G, Wu Y, Chen X, Guo X, et al. Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04255-1

BibTeX
@article{Zhang2025,
  author = {Zhang, Zhenzhen and Wang, Meixia and Chen, Guobin and Wu, Yanfang and Chen, Xiaochun and Guo, Xinkun and Zhang, Boheng},
  title = {Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04255-1}
}
Kostenlos starten →